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Abstract
Background—The number of states proposing school-entry requirements for human 
papillomavirus (HPV) vaccination has increased over the last decade. However, data are currently 
limited regarding parents' support of such laws. We sought to obtain the first national estimates of 
parents' support of HPV vaccination school-entry requirements.
Methods—A national sample of 1501 parents of 11- to 17-year-old children completed a web-
based survey between November 2014 and January 2015. Analyses used multivariable logistic 
regression to assess correlates of support for school-entry requirements for HPV vaccination.
Results—Overall, 21% of parents agreed that laws requiring HPV vaccination for school 
attendance "are a good idea," and 54% disagreed. If school-entry requirements included opt-out 
provisions, agreement increased to 57%, and only 21% disagreed. Parents more often agreed with 
requirements without opt-out provisions if they were Hispanic (OR=1.53, 95% CI: 1.05–2.22), 
believed HPV vaccine was as or more important than other adolescent vaccines (OR=2.76, 95% 
CI: 1.98–3.83), or believed HPV vaccine was effective for preventing cervical cancer (OR=2.55, 
95% CI: 1.93–3.37). Parents less often agreed if they resided in Midwest states or believed that 
HPV vaccine was being pushed to make money for drug companies (both p<.05).
Correspondence: Noel T. Brewer, Department of Health Behavior, Gillings School of Global Public Health, University of North 
Carolina, 325A Rosenau Hall CB 7440, Chapel Hill, NC 27599. Phone: 919-966-3282; Fax: 919-966-2921; ntb@unc.edu. 
Disclosure of Potential Conflicts of Interest: The other authors of this paper have no financial disclosures or potential conflicts of 
interest to report.
HHS Public Access
Author manuscript
Cancer Epidemiol Biomarkers Prev. Author manuscript; available in PMC 2017 September 
01.
Published in final edited form as:
Cancer Epidemiol Biomarkers Prev. 2016 September ; 25(9): 1317–1325. doi:
10.1158/1055-9965.EPI-15-1159.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Conclusion—Opt-out provisions almost tripled parents' support for HPV vaccine school-entry 
requirements. Our findings suggest that race/ethnicity, attitudes about HPV vaccine, and region of 
residence may influence support for requirements without opt-out provisions.
Impact—Opt-out provisions greatly increase parent support of school-entry requirements for 
HPV vaccination but may make them ineffective.
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Introduction
Human papillomavirus (HPV)-attributable diseases are a serious public health threat in the 
U.S (1). Nearly 80 million Americans are infected with at least one type of HPV (2), and 
HPV types 16 and 18 are responsible for more than 22,000 new cases of cancer each year 
(3). Most HPV-associated cancers could be prevented through widespread HPV vaccination 
(1). For this reason, national guidelines recommend routine and timely HPV vaccination of 
boys and girls at age 11 or 12 (4). However, HPV vaccine coverage is low, lagging far 
behind other adolescent vaccines. Among 13- to 17-year-olds, only 40% of girls and 22% of 
boys had completed the HPV vaccine series by 2014 (5). These coverage levels fall 
considerably short of the Healthy People 2020 goal of having 80% of 13- to 15-year-olds 
fully vaccinated (6).
In the U.S., policy interventions, such as school-entry requirements, have contributed to high 
uptake of adolescent vaccination and, in turn, low prevalence of many vaccine-preventable 
diseases (7–9). The Task Force on Community Preventive Services recommends school-
entry requirements as an evidence-based strategy to increase vaccine coverage (10). 
Requiring vaccination as a condition to school attendance is within state’s legislative power 
to protect the public’s health. As of 2016, all 50 states and Washington, D.C. have vaccine 
requirements for school entry. All of these laws allow for medical exemptions (11), which 
typically require a physician’s certificate stating that a vaccination would be harmful. Most 
states also allow nonmedical exemptions; 47 states permit religious exemptions and 18 states 
allow philosophical exemptions on the basis of personal, moral or other beliefs against 
vaccination (11). States differ in the process parents must go through to get a nonmedical 
exemption (12–14). In states where there is no rigorous process for claiming the exemption, 
more people opt out of vaccination (15).
The unprecedented opportunity to prevent HPV-associated cancers through vaccination led 
many states to propose laws requiring HPV vaccine for school attendance, similar to those 
for tetanus, diphtheria, and pertussis (Tdap). Since Michigan introduced the first legislation 
requiring HPV vaccination for school entry in September 2006, 24 other states and 
Washington, D.C. have proposed similar laws (16). However, only Virginia and Washington, 
D.C. have enacted such legislation into law, with Rhode Island more recently adopting the 
policy by means of administrative ruling. Ethical, political, and legal concerns from 
opponents have been the focus of the policy debate (17–19), shifting discussions away from 
the demonstrated effectiveness of HPV vaccination to prevent many cancers (20, 21).
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Policymakers consider their constituents’ opinions as they decide how to act on health 
policies (22), including HPV vaccination school-entry requirements (17). However, data are 
currently limited regarding parents’ support for these laws. Previous studies were limited to 
samples in Georgia (23), North Carolina (24), and Los Angeles, California (25) and 
happened prior to ACIP recommendations that boys routinely receive HPV vaccination. To 
fill this large gap in the literature, we conducted a national survey among parents of 11- to 
17-year-old boys and girls to better understand their support for these laws. The aims of our 
study were to: 1) assess parents’ support for HPV vaccine school-entry requirements, 
without and with opt-out provisions, and 2) identify correlates of parental support for such 
laws. We hypothesized higher support for school-entry requirements when including opt-out 
provisions and among parents with positive attitudes about HPV vaccine.
Materials and Methods
Participants and Procedures
Participants were members of an existing, national panel of non-instutionalized U.S. adults 
maintained by a survey research company (26). The company constructed the panel using 
probability-based sampling of list-assisted, random-digit dialed (RDD) phone numbers 
supplemented by address-based sampling (ABS). The ABS strategy was incorporated in 
response to the growing number of cell phone-only households that are outside the 
traditional RDD landline telephone frame. Thus our overall sampling design captured 
households with landline phones, cell phone-only households, and households without 
telephones. Eligible panel members were parents of at least one 11- to 17-year-old child 
living primarily in their households. The survey instructed respondents with more than one 
age-eligible child to respond with regard to the child with the most recent birthday.
The survey company emailed invitations to a random sample of 2,845 panel members, and 
1,760 responded by visiting the survey website, confirming eligibility criteria, and providing 
informed consent. A total of 1,504 parents were eligible and completed the survey between 
November 2014 and January 2015. After accounting for ineligible respondents (n=335) and 
excluding respondents who failed to complete at least two-thirds of the survey (n=14), the 
survey response rate was 61%, calculated using American Association for Public Opinion 
Research Response Rate 5 (27). For the present study, we also excluded respondents who 
did not provide data on the main outcome variable (n=3). The final analytic sample had 
1,501 parents. Forty-three respondents (3% of the sample) came from Virginia and 
Washington, D.C., which had HPV vaccine school-entry requirements in place at the time of 
the survey. Since we sought to obtain the first national estimate of support for such 
requirements, we included these parents in our sample.
Prior to fielding the survey, we cognitively tested our instrument with 18 parents of 
adolescents to maximize respondent comprehension. We then pre-tested the survey online 
with 26 panel members to ensure proper functioning. The survey instrument is available 
online at www.unc.edu/~ntbrewer/hpv.htm. The University of North Carolina Institutional 
Review Board approved the study protocol.
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Measures
Following the approach of previous studies (24, 25), our survey introduced respondents to 
HPV vaccine school-entry requirements with the prompt, "Some states are trying to pass 
laws that would require all 11 and 12 year-olds to get HPV vaccine before they are allowed 
to start 6th grade.” Parents then said whether they agreed with the statement, “I think these 
laws are a good idea” using a 5-point response scale. Parents who did not agree with the 
previous statement received an additional item: “It is okay to have these laws only if parents 
can opt out if they want to.” For each statement, we categorized parents as agreeing 
(somewhat or strongly agree) or disagreeing/neither (somewhat or strongly disagree, or 
neither disagree or agree).
The survey assessed key candidate correlates previously identified in the literature as 
potential predictors of parental support of HPV vaccine school-entry requirements (24, 25). 
The survey company provided data on parents’ sex, race/ethnicity, educational attainment, 
annual household income, and location of residence in terms of U.S. state and region. We 
created a variable to assess whether respondents had their residence in a state that requires 
HPV vaccination for school attendance. We dichotomized this variable as yes (respondents 
from Virginia and Washington, D.C.) and no (respondents from other states). The survey 
also assessed the sex and age of the index child, and whether parents had received a provider 
recommendation for HPV vaccination for that child. The survey assessed HPV vaccination 
status with one item: “How many shots of the HPV vaccine has [child’s name] had?” We 
defined HPV vaccine initiation as responses of ≥1 shots.
Rules or regulations (e.g., requiring vaccination for school attendance) that people perceive 
as threatening personal freedoms can elicit a motivational state, reactance, which is 
characterized by anger and counter arguing and may elicit oppositional behavior (e.g., 
refusing vaccination) (28). The survey assessed psychological reactance with three items: “I 
become frustrated when I am unable to make free and independent decisions,” “Regulations 
trigger a sense of resistance in me,” and “When someone forces me to do something, I feel 
like doing the opposite.” These items had a 5-point response scale that ranged from 
“strongly disagree” to “strongly agree”. We created an index of reactance by calculating the 
mean response value and creating two categories: low (<4) and high (4–5).
The survey assessed parents’ agreement with statements shown to be associated with HPV 
vaccination uptake in the U.S. (29) and support for school-entry requirements for HPV 
vaccination (24, 25). The survey assessed perceptions regarding harms of HPV vaccines 
(e.g., "The HPV vaccine might cause lasting health problems"), barriers to vaccination (e.g., 
“It would be hard to find a provider or clinic where I can afford HPV vaccine for my child"), 
vaccine effectiveness (e.g., “The HPV vaccine is effective in preventing cervical cancer”), 
and uncertainty about the vaccine (e.g., "I don’t have enough information about the HPV 
vaccine to decide whether to give it to my child"). We adapted these items from the Carolina 
HPV Immunization Attitudes and Beliefs Scale (29). The 5-point response scale ranged 
from “strongly disagree” to “strongly agree.”
The survey also assessed importance of HPV vaccination with the statement: “I felt that the 
HPV vaccine for [child’s name] is…,” accompanied by a 5-point response scale that ranged 
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from “not important” to “extremely important.” The survey repeated the same statement for 
meningococcal and Tdap vaccines. We calculated relative vaccine importance, giving a score 
of 1 if parents rated HPV vaccine as important as, or more important than, the average score 
for Tdap and meningococcal vaccines and 0 otherwise.
Statistical analysis
We calculated the percentage of support for HPV vaccine school-entry requirements, 
without and with opt-out provisions. We used bivariate logistic regressions to identify 
bivariate associations of candidate correlates with support for HPV vaccine requirements. 
We then entered covariates showing associations (p<.05) in bivariate analyses into a 
multivariable logistic regression model. We used separate logistic regression models to 
assess the associations between potential correlates and HPV vaccine requirements without 
and with opt-out provisions. Statistical tests were two-tailed with a critical alpha of .05. We 
conducted analyses using Stata 12.0 (College Station, TX).
Results
Respondents included residents of all 50 states and Washington D.C., and 33% were from 
the South (Table 1). About one-fifth (22%) had a household income of less than $35,000 per 
year. Parents were evenly split between having reported on a son (51%) or a daughter (49%), 
and the mean age of children was 14 years. Forty-six percent of children had received at 
least 1 dose of HPV vaccine. Fifty-six percent of parents were female, and the majority were 
non-Hispanic white (70%) or Hispanic (14%). More than one-third (38%) of parents had a 
high school degree or less education. Almost three-fourths (73%) of the sample scored low 
in the 3-item index of psychological reactance. About half (52%) of parents had received a 
provider recommendation for HPV vaccination.
Regarding HPV vaccine attitudes, about half (51%) of parents said that HPV vaccine was as 
or more important than the Tdap and meningococcal vaccines (Table 1). Nearly one-fourth 
(23%) of the sample thought that HPV vaccine might cause lasting health problems and 
about one-third (32%) thought that HPV vaccine was being pushed to make money for drug 
companies. Thirty-two percent of parents said that they did not have enough information 
about HPV vaccine to decide whether to vaccinate their children and only 40% agreed that 
the vaccine was effective in preventing cervical cancer. Few parents (6%) said that it would 
be hard to find a provider or clinic where they can afford HPV vaccine for their children.
Support for HPV vaccine requirements without opt-out provisions
Twenty-one percent of parents agreed that laws requiring HPV vaccination for school 
attendance "are a good idea" (Figure 1). Hispanic parents had higher odds (OR=1.53, 95% 
CI: 1.05–2.22) of agreeing with HPV vaccine school-entry requirements than non-Hispanic 
whites in multivariable analysis (Table 2). Likewise, parents more often agreed with these 
requirements if they believed that HPV vaccine was as or more important than other 
adolescent vaccines (OR=2.76, 95% CI: 1.98–3.83), that HPV vaccine was effective for 
preventing cervical cancer (OR=2.55, 95% CI: 1.93–3.37), or that it would be hard to find a 
provider or clinic where they can afford the vaccine for their children (OR=2.50, 95% CI: 
Calo et al. Page 5
Cancer Epidemiol Biomarkers Prev. Author manuscript; available in PMC 2017 September 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
1.45–4.33). On the other hand, parents less often agreed with school-entry requirements if 
they believed that HPV vaccines were being pushed to make money for drug companies 
(OR=0.47, 95% CI: 0.32–0.69) or resided in Midwest states compared to Northeast states 
(OR=0.64, 95% CI: 0.42–0.98). In bivariate but not multivariate analyses, agreement with 
school-entry requirements was associated (p<.05) with living in a state requiring HPV 
vaccination for school attendance, having initiated HPV vaccination, having received a 
provider recommendation for HPV vaccination, lower psychological reactance, and 
believing that HPV vaccine might cause lasting health problems and that respondents do not 
have enough information to decide whether to give the vaccine to their children.
Support for HPV vaccine requirements that include opt-out provisions
Support for HPV vaccine school-entry requirements increased to 57% when including 
parents who agreed "these laws are okay only if parents can opt out" (Figure 1). Support for 
HPV vaccine requirements also increased when examined for each variable independently 
associated with agreeing that school-entry requirements “are a good idea” (Figure 2). In 
multivariable analysis, when including agreement with opt-out provisions, parents who 
believed HPV vaccine was effective in preventing cervical cancer (OR=2.18, 95% CI: 1.73–
2.74) and believed HPV vaccine was as or more important than Tdap and meningococcal 
vaccines (OR=1.29, 95% CI: 1.02–1.66) still had higher odds of agreeing with school-entry 
requirements (data not shown). When opt-out provisions were included, no other variable 
associated with agreeing school-entry requirements “are a good idea” remained associated in 
multivariable analysis.
Discussion
The present study, to our knowledge, is the first to employ a national sample to assess 
parental attitudes about HPV vaccine school-entry requirements. We found that 21% of 
parents agreed that school-entry requirements “are a good idea.” Previous studies reported 
higher levels of support than we observed; 46% of parents in five southeastern North 
Carolina counties (24) and 59% in Los Angeles (25) agreed with HPV vaccine school-entry 
requirements. However, such levels of support could be particular to those study participants 
and may not be generalizable to the general population because data were collected from 
individuals who lived in counties with elevated cervical cancer rates (25) or participated in a 
study about sexually transmitted infections (24). In addition, previous estimates of support 
could be higher because the response scale did not have a midpoint response option, thus 
requiring participants to take either side of the agree or disagree scale. In the present study, 
we found that 25% of the sample neither agreed nor disagreed with HPV vaccine school-
entry requirements. Although some scholars debate that providing this response option 
makes it easier to respondents to avoid the mental process necessary to select their true 
response (30), other also argue that not everyone has strong thoughts one way or the other, 
even for very polarized policy issues (31). Public education and social marketing campaigns 
may be important for increasing support among parents who held middle-of-the-road 
attitudes about HPV vaccine requirements (32, 33).
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Agreement with HPV vaccine school-entry requirements almost tripled when opt-out 
provisions were mentioned to parents, and disagreement decreased from 54% to 21%. 
Although vaccine opt-out provisions vary across state jurisdictions, in general, such 
provisions allow parents to refuse vaccination for any reasons. Previous research showed 
that some parents opt out vaccination for their child, or file non-medical exemptions, 
because opting out is far more convenient than completing the immunization schedule for 
school attendance (34). Broader opt-out provisions for HPV vaccination may have the effect 
of creating a culture of vaccine refusal and may lead parents to seek exemptions for other 
vaccines (19, 35). In Virginia and Washington, D.C., parents have broad authority to opt out 
HPV vaccination, but procedures vary by jurisdiction. Although both jurisdictions provide 
parents with information about HPV infection and the benefits of vaccination, only 
Washington, D.C. requires parents to sign a standardized form to opt out HPV vaccination. 
The impact of this process on HPV vaccination is unknown. The 2014 National 
Immunization Survey–Teen (NIS-Teen) shows that Virginia’s coverage for HPV vaccine 
initiation (59%) and 3-dose series completion (36%) for females aged 13–17 were below 
national averages (60% and 39%, respectively) (5). On the other hand, Washington, D.C. had 
one of the highest coverage levels for HPV vaccine initiation (75%) and completion (57%) 
in the U.S. Research is needed to investigate the extent to which different forms of opt-out 
provisions may contribute to or detract from vaccination.
A growing number of states are tightening opt-out provision and non-medical exemption 
requirements (36). Several states, for example, require parents to submit documentation that 
they received information about the benefits and risks of vaccination from health care 
providers before opting out (37). Similar informational steps and application processes 
might be added to existing and future HPV vaccine school-entry requirement laws to reduce 
the likelihood that parents will opt-out vaccination solely for convenience. It is also 
important to note that vaccine advocates have expressed caution that a poorly timed push for 
HPV vaccine school-entry requirements or changes in opt-out provision rules might provoke 
a public backlash (13, 18). In light of previous failures legislating HPV vaccine 
requirements, such policies should be judiciously conceived and well supported by key 
stakeholders (13, 17).
Our data showed that parents were less likely to agree with HPV vaccine school-entry 
requirements if they resided in Midwest states compared to Northeast states. This finding is 
novel in the literature because no previous research has examined support for such 
requirements across U.S. regions or states. Public support for school-entry requirements is 
key for state legislatures to introduce and enact such proposals (17), so understanding 
parents’ attitudes towards these requirements is important for informing state policy 
discussions. An analysis of HPV vaccine legislation reveals different patterns of legislative 
activity across U.S. regions (16). Since 2006, only half of the 12 states comprising the 
Midwest region introduced legislation requiring HPV vaccination for school attendance, and 
none of those policies was subsequently considered for enactment. In contrast, two-thirds of 
the 9 states in the Northeast region introduced legislation to adopt HPV vaccine school-entry 
requirements with Rhode Island successfully passing an administrative policy on the matter. 
Alternatively, three quarters of Midwestern states enacted laws to fund or educate the public 
or school children about HPV vaccination versus only a third of states in the Northeast 
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region. Taken together, these data suggested that Midwest states have responded introducing 
and enacting legislation aimed to increase funding and information about the vaccine rather 
than require HPV vaccination for school entry. Our finding that parents living in the 
Midwest expressed low levels of support for HPV vaccine school-entry requirements may 
shed some light with regard to the failure of state legislatures in introducing and passing 
such legislation. Although, in the absence of school-entry requirements, other laws alone are 
unlikely to considerably raise HPV vaccine coverage rates, laws to increase awareness of 
and access to HPV vaccination may serve to complement state immunization programs (38). 
Research on the public’s opinions about a range of HPV vaccine policy strategies is needed 
to ensure that new legislative developments are carefully conceived and supported by state’s 
constituents.
Support for school-entry requirements was higher among Hispanic parents compared to 
other racial/ethnic groups. This finding is consistent with a previous study showing that 
HPV vaccine requirements for school entry were highly acceptable to Hispanics (25, 39). 
Data from the 2014 NIS-Teen showed higher rates of HPV vaccine initiation and 3-dose 
completion among Hispanic adolescents aged 13–17 than their non-Hispanic white 
counterparts (5). Hispanics’ cultural factors may explain their higher uptake of HPV vaccine 
and greater agreement with school-entry requirements compared to other populations (40). 
Robitz et al. (25) argued that Hispanics had a strong “respect for authority figures” and so, 
Hispanic parents may be more likely to agree with vaccine requirements because they are 
more likely to follow advice from health care professionals. Although we were unable to 
assess the effect of any cultural factors on the level of support for HPV vaccine school-entry 
requirements, previous data showed that Hispanic parents responding to survey research in 
Spanish were more supportive of such immunization requirements than those responding in 
English (25). Interestingly, other studies show a more positive effect of acculturation with 
regard to HPV vaccination. Gerend et al. (41), for example, reported that Hispanic parents 
who are more acculturated into U.S. society were more likely to get the HPV vaccine for 
their daughters. The specific mechanisms that account for the relationships between 
Hispanic ethnicity, acculturation, HPV vaccine uptake, and support for school-entry 
requirements are understudied. Nonetheless, the finding that Hispanics are consistently more 
supportive of HPV vaccine school-entry requirements suggests that Hispanic communities 
might be important partners in advocacy and vaccine campaign mobilization efforts.
We found that parents who believed HPV vaccine was as or more important than other 
adolescent vaccines were more likely to support school-entry requirements. In previous 
surveys we conducted with family physicians and pediatricians (42, 43), many reported that 
they endorse HPV vaccine less strongly than Tdap or meningococcal vaccines, often discuss 
it last, or recommend the vaccine as an optional vaccine. These low quality recommendation 
practices not only discourage parents from vaccinating their children but may also add 
distrust and suspicion with regard to HPV vaccine policies. Since physicians are an 
important source of vaccine information for parents (44, 45), better physician’s 
communication practices about HPV vaccine in relation to other adolescent vaccines may 
influence parents’ opinions about school-entry requirements. We also found that parents who 
had favorable perceptions of HPV vaccine effectiveness were more likely to support school-
entry requirements. Our finding is consistent with previous research (25) and highlights the 
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importance of continuing to communicate that the vaccine is a safe and effective health 
service to prevent cervical cancer, which kills 4,000 U.S. women each year. Since HPV 
vaccine is recommended for boys and girls, information about parents’ perceptions of 
vaccine effectiveness in preventing other HPV-attributable cancers may be important to 
increase support for school-entry requirements. Consistent with previous studies (24, 25), 
concerns about the involvement of drug companies in pushing HPV vaccination to make 
money were also associated with parents’ opinions about HPV vaccine school-entry 
requirements. Many authors argued that drug company lobbying, while not illegal, fueled the 
public belief that school-entry requirements were legislated solely to benefit such companies 
(18, 21). Our finding suggests that efforts for maintaining public trust in public health 
systems are crucial both for improving HPV vaccination and for the viability of legislating 
school-entry requirements.
Strengths of this research include a large, national sample of parents and a good survey 
response rate. In addition, the present study is the first to assess support for HPV vaccine 
school-entry requirements after the ACIP recommended that boys be routinely vaccinated. 
This study had several limitations. The survey asked about hypothetical school-entry 
requirements, rather than actual laws, and did not describe the scope of opt-out provisions. 
Parents’ support for school-entry requirements could differ when asked about actual 
legislation and may vary by type of opt-out provision (medical, religious, or philosophical 
exemptions). Future research should explore how support for school-entry requirements and 
correlates of parental support change with different types of opt-out provisions. The sample 
included 70% non-Hispanic Whites, which is a slightly higher proportion than the 62% of 
U.S. adults who identify themselves as such. Even so, our sample included meaningful 
numbers of non-Hispanic Black (9%) and Hispanic (14%) respondents, making this survey 
more racially and ethnically diverse than previous studies on this topic. Another limitation is 
that the survey was administered in English, so participants with limited English proficiency 
might have faced difficulties interpreting or responding to survey questions. Although 
participants needed an email account to receive an invitation to participate in the survey, the 
survey company facilitated the participation of respondents with lower access to technology 
by providing a laptop computer and free Internet access to those panel members who lacked 
these resources.
Although we focused on parents, we acknowledge that there are other key stakeholders 
contributing to policy considerations surrounding HPV vaccine school-entry requirements. 
Developing sound policy will require incorporating the perspectives of policymakers 
including whether these requirements should include nonmedical exemptions and, in such a 
case, the ease with which these opt-out provisions can be obtained by parents and reviewed 
by state officials (17). Research is needed to identify influential factors in determining how 
policymakers act on the issue of HPV vaccine requirements. Importantly, the perspectives of 
medical associations, state health departments, and school districts are also influential to the 
policymaking process. A recent study showed that 47% of physicians who provide primary 
care, including vaccines, to adolescents support HPV vaccine school-entry requirements 
(46). These stakeholders have been key actors advocating about health policies in the U.S 
(47). Because school-entry requirements are legislated on a state-by-state basis in the U.S., 
challenges arise with regard to the capacity of states to provide school-required vaccines, 
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monitor compliance, and enforce such policies (48). Our study provides key information 
about the perspectives of parents towards HPV vaccine school-entry requirements, which 
can inform state policy discussions about this important topic.
Conclusion
Improving HPV vaccination coverage is a national priority. While school-entry requirements 
have proven to be a valuable policy mechanism to raise childhood and adolescent 
vaccination coverage in the U.S., they have also engendered controversy and debate in the 
case of HPV vaccination. Although school-entry requirements are viewed by some parents 
as an interference with parental autonomy and freedom of choice (21), through the years, 
other types of public health legislation (e.g., smoking restrictions, car seat belts, motorcycle 
helmets) have succeeded in the face of similar concerns (49). As many scholars suggest, 
before proposing HPV vaccine requirements states must strengthen their immunization 
programs and ensure that their constituents understand the benefits of HPV vaccination (18, 
50). Likewise, the National Vaccine Advisory Committee recommends that states 
considering HPV vaccine school-entry requirements consider a range of issues including 
vaccine infrastructure and financing, disease burden and epidemiology, existing vaccine 
policies, and political and public support (35, 51). Thorough consideration of such issues 
will allow policymakers to address critical elements related to HPV vaccine requirements in 
order to ensure that new legislative proposals are carefully designed and supported by the 
public. Our study provides the first national assessment of parents’ attitudes about HPV 
vaccine school-entry requirement; our findings suggest that distinctive characteristics of the 
population may influence support for such laws. Support of school-entry requirements for 
HPV vaccination continues to be contingent upon the inclusion of opt-out provisions, which 
may negatively impact the effectiveness of these laws.
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Figure 1. 
Agreement with school-entry requirements for HPV vaccine.
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Figure 2. 
Parental support for school-entry requirement laws with and without opt-out provisions.
NOTE: Black bars show the proportion of parents agreeing that HPV vaccine requirements 
“are a good idea,” when opt-out provisions were not mentioned in the statement, and white 
bars show the additional proportion of parents agreeing that “these laws are okay only if 
parents can opt out if they want to.”
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Table 1
Characteristics of a national sample of parents of 11- to 17-year-old adolescents, 2014–2015 (N=1,501).
N %
Household characteristics
Income
  <$35,000 329 22
  $35,000 – $74,999 467 31
  ≥$75,000 705 47
Region
  Northeast 261 17
  Midwest 392 26
  South 497 33
  West 351 23
Resident of state that requires HPV vaccination for school
attendance 43 3
Child characteristics
Female 738 49
Age (years)
  11–12 420 28
  13–17 1,081 72
HPV vaccination status
  0 doses 807 54
  ≥1 dose 694 46
Parents’ characteristics and attitudes about HPV vaccine
Female 835 56
Race/Ethnicity
  Non-Hispanic White 1,056 70
  Non-Hispanic Black 134 9
  Hispanic 212 14
  Other 99 7
Education
  High school degree or less 574 38
  Some college 389 26
  Bachelor’s degree or higher 538 36
Psychological reactance
  Low 1,089 73
  High 412 27
Has a doctor or other health care provider ever told your child
should get the HPV vaccine?
  No 721 48
  Yes 780 52
Relative importance of HPV vaccine compared to Tdap and
meningococcal vaccines
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N %
  Less important 736 49
  As or more important 765 51
The HPV vaccine might cause lasting health problems.
  Disagree/neither 1,153 77
  Agree 348 23
The HPV vaccine is being pushed to make money for drug
companies.
  Disagree/neither 1,022 68
  Agree 479 32
I don’t have enough information about the HPV vaccine to
decide whether to give it to my child.
  Disagree/neither 1,022 68
  Agree 479 32
The HPV vaccine is effective in preventing cervical cancer.
  Disagree/neither 900 60
  Agree 601 40
It would be hard to find a provider or clinic where I can afford
HPV vaccine for my child.
  Disagree/neither 1,419 94
  Agree 82 6
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Table 2
Correlates of parental agreement for HPV vaccine school-entry requirements (N=1,501).
No. respondents who
agreed with “I think
these laws are a
good idea” (%)
Bivariate OR
(95% CI)
Multivariable OR
(95% CI)
Household characteristics
Income
  <$35,000 79/329 (24) Ref -
  $35,000 – $74,999 95/467 (20) 0.81 (0.58, 1.13) -
  ≥$75,000 147/705 (21) 0.83 (0.61, 1.14) -
Region
  Northeast 65/261 (25) Ref Ref
  Midwest 60/392 (15) 0.54 (0.37, 0.81)** 0.64 (0.42, 0.98)*
  South 113/497 (23) 0.89 (0.63, 1.26) 0.92 (0.62, 1.36)
  West 83/351 (24) 0.93 (0.64, 1.36) 0.88 (0.58, 1.33)
Resident of state that requires HPV vaccination for school
attendance
  No 306/1,458 (21) Ref Ref
  Yes1 15/43 (35) 2.01 (1.06, 3.82)* 1.68 (0.81, 3.48)
Child characteristics
Sex
  Male 172/763 (23) Ref -
  Female 149/738 (20) 0.87 (0.68, 1.11) -
Age (years)
  11–12 93/420 (22) Ref -
  13–17 228/1081 (21) 0.94 (0.72, 1.23) -
HPV vaccination
  0 doses 107/807 (13) Ref Ref
  ≥1 dose 214/694 (31) 2.92 (2.25, 3.78)** 1.33 (0.95, 1.86)
Parents’ characteristics and attitudes about HPV vaccine
Sex
  Male 151/666 (23) Ref -
  Female 170/835 (20) 0.87 (0.68, 1.12) -
Race/Ethnicity
  Non-Hispanic White 198/1,056 (19) Ref Ref
  Non-Hispanic Black 31/134 (23) 1.30 (0.85, 2.01) 0.98 (0.61, 1.58)
  Hispanic 67/212 (32) 2.00 (1.44, 2.78)** 1.53 (1.05, 2.22)*
  Other 25/99 (25) 1.46 (0.91, 2.36) 1.16 (0.69, 1.98)
Education
  High school degree or less 125/574 (22) Ref -
  Some college 73/389 (19) 0.83 (0.60, 1.15) -
  Bachelor’s degree or higher 123/538 (23) 1.06 (0.80, 1.41) -
Cancer Epidemiol Biomarkers Prev. Author manuscript; available in PMC 2017 September 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Calo et al. Page 19
No. respondents who
agreed with “I think
these laws are a
good idea” (%)
Bivariate OR
(95% CI)
Multivariable OR
(95% CI)
Psychological reactance
  Low 251/1,089 (23) Ref Ref
  High 70/412 (17) 0.68 (0.51, 0.92)* 0.99 (0.71, 1.37)
Has a doctor or other health care provider ever told your
child should get the HPV vaccine?
  No 114/721 (16) Ref Ref
  Yes 207/780 (27) 1.92 (1.49, 2.48)** 1.13 (0.82, 1.55)
Relative importance of HPV vaccine compared to Tdap
and meningococcal vaccines
  Less important 74/736 (10) Ref Ref
  As or more important 247/765 (32) 4.27 (3.21, 5.67)** 2.76 (1.98, 3.83)**
The HPV vaccine might cause lasting health problems.
  Disagree/neither 279/1,153 (24) Ref Ref
  Agree 42/348 (12) 0.43 (0.30, 0.61)** 0.71 (0.47, 1.08)
The HPV vaccine is being pushed to make money for
drug companies.
  Disagree/neither 270/1,022 (26) Ref Ref
  Agree 51/479 (11) 0.33 (0.24, 0.46)** 0.47 (0.32, 0.69)**
I don’t have enough information about the HPV vaccine
to decide whether to give it to my child.
  Disagree/neither 247/1,022 (24) Ref Ref
  Agree 74/479 (16) 0.57 (0.43, 0.76)** 1.14 (0.80, 1.62)
The HPV vaccine is effective in preventing cervical
cancer.
  Disagree/neither 117/900 (13) Ref Ref
  Agree 204/601 (34) 3.44 (2.66, 4.45)** 2.55 (1.93, 3.37)**
It would be hard to find a provider or clinic where I can
afford HPV vaccine for my child.
  Disagree/neither 290/1,419 (20) Ref Ref
  Agree 31/82 (38) 2.37 (1.49, 3.77)** 2.50 (1.45, 4.33)**
NOTE: HPV = Human papillomavirus; OR = Odds ratio; CI = confidence interval; Ref = Referent group. Dashes (−) indicate the variable was not 
included in the multivariable model because it was not statistically significant at the bivariate level.
1
Respondents from Virginia and Washington, DC. Rhode Island did not have a school-entry requirement at the time of data collection.
*p < .05;
**p < .01
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